FinanceHealth-ITNews

Delhi-based Bioheaven360 Genotec secures Rs 1 crore funding from DFAN

In 2023, it plans to add more products in the microbiology and molecular domain and expand its reach across India and release for testing the immuno-molecules

Bioheaven360 Genotec, a biotechnology company focussed on developing next-generation diagnostics and immuno-theranostics through genomics, recombinant DNA technology, and AI, has secured Rs 1 crore in funding from DFAN, a global community-backed angel network.

THIS CAN BE YOUR ADVERTISEMENT

Bioheaven360 will use this funding to expand its facility and infrastructure for the production of medical devices, as well as continue the development of its innovative state-of-the-art products.

Bioheaven360’s long-term vision is to discover new cost-effective molecules for treating dreadful diseases and using AI-based data insights to enhance medical practices, predict risks early, and help people live longer healthier lives. Bioheaven360 desires to become one of the biggest biotech companies in the world.

In 2023, it plans to add more products in the microbiology and molecular domain and expand its reach across India and release for testing the immuno-molecules.

Shailendra Vyas, Director, Bioheaven, said, “We are thrilled to receive this funding from DFAN, which will allow us to accelerate our growth and bring our innovative medical technologies to market and enable us to take significant steps towards achieving our long-term vision and short-term goals. We believe that our innovative approach to biotechnology will make a real difference in the lives of people suffering from critical diseases.”

“As BioHeaven, a biotechnology start-up uses technology in their core business. Digital Futurists Angel Network (DFAN) has chosen to invest in this as we are part of the vision to leverage technology for effective and safe biotech. We are always looking for highly innovative, scalable solutions that can be adapted and scaled globally. With an increase in infectious pathogens, complicated regulatory oversight and increased need for state-of-the-art technology for high-quality products in diagnostics and therapeutics, DFAN is pleased to partner with BioHeaven which has a strong presence in the growing market,” mentioned Ganesh Viswanathan, Director, DFAN

Bioheaven360 is a leading biotechnology company at the forefront of medical innovation, developing technologies shaping a brighter future. The company is dedicated to improving healthcare through cutting-edge solutions with wide-ranging applications and cost-effective solutions.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close